BiomX Inc. (PHGE)

BiomX Inc. implemented a 1-for-19 reverse stock split on November 25, 2025. The Phase 2b BX004 trial was discontinued on December 8, 2025, leading to a stock decline of 36.94%. A $3.0 million private placement was announced on December 29, 2025. On January 27, 2026, the company addressed unusual market activity in its common stock. The FDA placed a clinical hold on the U.S. Phase 2b trial for BX004 in August 2025, but provided positive feedback in October 2025. Wall Street analysts have issued a "Buy" consensus for PHGE, with HC Wainwright & Co. reiterating a "Buy" recommendation in November 2025.

Information regarding demand seasonality for BiomX, Inc.'s products is not readily available. As a clinical-stage biopharmaceutical firm without commercial products, traditional demand seasonality does not apply. Its financial stability is driven by capital raises and non-dilutive grant funding.

BiomX Inc. is a clinical-stage biopharmaceutical company focused on developing phage technologies to target and eliminate harmful bacteria associated with chronic diseases, operating within the Healthcare sector and Biotechnology industry. BX211 is in Phase 2 for diabetic foot osteomyelitis, with positive results showing ulcer size reduction. BX004 is in Phase 1b/2a trials for cystic fibrosis and bronchiectasis patients with pulmonary infections, with Phase 2b trial initiated in July 2025. The XMarker Platform identifies biomarkers for inflammatory bowel disease drug development and is used in collaboration with Boehringer Ingelheim.

BiomX Inc. is headquartered in Ness Ziona, Israel, with a U.S. office in Cambridge, Massachusetts, founded in 2015. Its clinical trials extend to Europe, where patient recruitment and dosing for the BX004 Phase 2b trial continue, despite a clinical hold in the U.S.

BiomX's brand reputation has seen positive analyst sentiment alongside challenges from clinical trial progress. The company received a "Buy" consensus from Wall Street analysts and a Zacks Rank #2 (Buy) upgrade in December 2025. However, the discontinuation of the Phase 2b BX004 trial and the FDA clinical hold have negatively impacted its reputation, leading to stock price declines. The company's statement regarding unusual stock trading activity could also be perceived cautiously by investors.

BiomX Inc. is a publicly-traded company with ownership distributed among institutional funds, company insiders, and the general public. Institutional investors held 44.48% of shares, the public float held 36.71%, and insider ownership was at 18.81% as of Q3 2025. Major institutional shareholders include UBS Group AG and Cwm, Llc. The CEO, Jonathan Solomon, directly owns 0.59% of the company's shares.